Gopa B, Bhatt J, Hemavathi KG
doi: 10.3389/fnut.2024.1371672 Received 16 January 2024 Accepted 22 April 2024 Published 04 June 2024 Volume 11 - 2024 Edited by zlem Emir oban, Firat University, Trkiye Reviewed by Aleksandar
On Monday, the FDA approved nirogacestat, to be marketed as Ogsiveo, as the first-ever therapy for this potentially painful and physically debilitating condition
Translation to human outcomes is not demonstrated
Myostatin Inhibitory Peptide 7 improves metabolism through the following mechanisms: Glucose metabolism: In the diabetic mouse model, MSTN-IP7 treatment reduced fasting blood glucose by 40% and increased insulin sensitivity by 35%
It is made in Chennai (formerly Madras), India